Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gordon Goolamier"'
Autor:
Petros Grivas, Behtash Ghazi Nezami, Thomas Giever, Gordon Goolamier, Matthew J. Riese, Adam Calaway, L. Ponsky, Emily Lemke, Kathryn A. Bylow, Deepak Kilari, John D. Burfeind, Mary Ann Draves, Ali Raza Khaki, Christopher J. Hoimes, Aniko Szabo, Leonidas Nikolaos Diamantopoulos, Samantha Rosey, Robert J. Cronk, Ariel Ann Nelson, Gregory T. MacLennan
Publikováno v:
Journal of Clinical Oncology. 38:e17007-e17007
e17007 Background: Outcomes of patients (pts) with mUC with EOM have not thoroughly been described in the age of immuno-oncology. We hypothesized that EOM is associated with worse outcomes when compared to pts with non-osseous metastases (NOM). Metho
Autor:
Hristos Z. Kaimakliotis, Gordon Goolamier, Adam Calaway, Edouard J. Trabulsi, Michael O. Koch, Zachary L. Smith, Mark D. Fleming, Pingfu Fu, Nabil Adra, L. Ponsky, Robert Abouassaly, Clint Cary, William Kevin Kelly, Jean H. Hoffman-Censits, Radhika Walling, Cheryl Eitman, Christopher J. Hoimes, Joel Picus
Publikováno v:
Journal of Clinical Oncology. 38:5047-5047
5047 Background: Patients (pts) with laUC who are C-eligible for N- therapy may benefit from combination chemo-immunotherapy. Cohort 1 (C1) of the GU14-188 trial is a phase 1b/2 trial designed to assess the tolerability and efficacy of N- gemcitabine
Autor:
L. Ponsky, William Kevin Kelly, Hristos Z. Kaimakliotis, Edouard J. Trabulsi, Adam Calaway, Timothy A. Masterson, Richard C. Lauer, Pingfu Fu, Joel Picus, Nabil Adra, Christopher J. Hoimes, Michael O. Koch, Cheryl Eitman, Zachary L. Smith, Gordon Goolamier, Radhika Walling, Elizabeth Sonderman
Publikováno v:
Journal of Clinical Oncology. 38:5019-5019
5019 Background: Patients (pts) with laUC who are C-ineligible have inferior survival compared to counterparts who receive C based N-therapy and have a pathologic response at radical cystectomy (RC). Cohort 2 (C2) of the GU14-188 trial is designed to